.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,883,986

« Back to Dashboard

Details for Patent: 8,883,986

Title:Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile ("C. difficile"), Clostridium perfringens ("C. perfringens"), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.
Inventor(s): Chiu; Yu-Hung (San Diego, CA), Che; Tessie Mary (San Diego, CA), Romero; Alex (San Diego, CA), Ichikawa; Yoshi (San Diego, CA), Shue; Youe-Kong (Carlsbad, CA)
Assignee: Optimer Pharmaceuticals, Inc. (Lexington, MA)
Filing Date:Mar 04, 2009
Application Number:12/397,686
Claims:1. A polymorphic crystalline form of a compound of Formula I: ##STR00010## characterized by: (i) a powder x-ray diffraction pattern comprising peaks at diffraction angles 2.theta. of 7.6.degree., 15.4.degree., and 18.8.degree..+-.0.1; and (ii) a Differential Scanning Calorimetry (DSC) endotherm in the range of about 150.degree. C. to about 158.degree. C.

2. A solid dosage form comprising the polymorphic crystalline form of a compound of Formula I of claim 1.

3. The solid dosage form of claim 2 wherein the polymorphic crystalline form of a compound of Formula I is present from about 75% to about 99.99% of the total weight of tiacumicins.

4. The solid dosage form of claim 2, wherein the polymorphic crystalline form of a compound of Formula I is present in about 90% of the total weight of tiacumicins.

5. A pharmaceutical composition comprising the solid dosage form of claim 2.

6. The pharmaceutical composition of claim 5 further comprising a pharmaceutically acceptable excipient.

7. The polymorphic crystalline form of the compound of Formula I of claim 1 wherein the DSC endotherm is in the range of about 153.degree. C. to about 156.degree. C.

8. A polymorphic crystalline form of a compound of Formula I: ##STR00011## produced by crystallizing the polymorphic crystalline form from a mixture of ethyl acetate and the compound of formula I, wherein the polymorphic crystalline form has a powder x-ray diffraction pattern comprising peaks at diffraction angles 2.theta. of 7.6.degree., 15.4.degree., and 18.8.degree..+-.0.1.

9. The polymorphic crystalline form of claim 8, wherein the ethyl acetate is allowed to evaporate to crystallize the polymorphic crystalline form.

10. The polymorphic crystalline form of claim 8, wherein the polymorphic crystalline form has a Differential Scanning Calorimetry (DSC) endotherm in the range of about 150.degree. C. to about 158.degree. C.

11. A solid dosage form comprising the polymorphic crystalline form of a compound of Formula I of claim 8.

12. The solid dosage form of claim 11 wherein the polymorphic crystalline form of a compound of Formula I is present from about 75% to about 99.99% of the total weight of tiacumicins.

13. The solid dosage form of claim 12, wherein the polymorphic crystalline form of a compound of Formula I is present in about 90% of the total weight of tiacumicins.

14. A pharmaceutical composition comprising the polymorphic crystalline form of claim 8 and a pharmaceutically acceptable excipient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc